On the stock market since 2025, it operates in the world of health and science. It has 99 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 59% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 18% a year on average.
Sales run at $13.6M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 26 buys and 17 sells. Management buying with its own money is usually read as a good sign.
A loss of $25.3M against $13.6M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CV is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (36/100) says the stock isn’t cheap.